{"id":"hs-25-and-atorvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Muscle pain or myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin reduces LDL cholesterol and triglycerides by inhibiting the rate-limiting enzyme in cholesterol synthesis. HS-25's specific mechanism is not publicly disclosed, but the combination is being evaluated in Phase 3 trials, likely for cardiovascular or metabolic indications. The exact mechanism of HS-25 and its synergy with atorvastatin requires access to clinical trial protocols.","oneSentence":"HS-25 is a combination therapy where HS-25 (an investigational agent) is co-administered with atorvastatin, a statin that inhibits HMG-CoA reductase to lower cholesterol.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:03.988Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia or cardiovascular disease (specific indication not publicly confirmed)"}]},"trialDetails":[{"nctId":"NCT03433196","phase":"PHASE3","title":"Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases","status":"COMPLETED","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2016-06-07","conditions":"Hypercholesterolemia in Coronaory Heart Disease","enrollment":255},{"nctId":"NCT03464682","phase":"PHASE3","title":"Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia","status":"UNKNOWN","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2015-02-28","conditions":"Primary Hypercholesterolemia","enrollment":720}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HS-25 and Atorvastatin","genericName":"HS-25 and Atorvastatin","companyName":"Zhejiang Hisun Pharmaceutical Co. Ltd.","companyId":"zhejiang-hisun-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HS-25 is a combination therapy where HS-25 (an investigational agent) is co-administered with atorvastatin, a statin that inhibits HMG-CoA reductase to lower cholesterol. Used for Hyperlipidemia or cardiovascular disease (specific indication not publicly confirmed).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}